FreeCME

Biological Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Osteoarthritis: Comparative Effectiveness Based on Treatment Profiles and Recommendations

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and MedNet.

Grantors:

AbbVie, Inc.
Janssen Biotech, Inc.,
UCB, Inc.

Release date: Sept. 25, 2015

Valid through: Sept. 25, 2016

Specialty: Rheumatology, Internal Medicine

Media: Internet

Estimated Time to Complete Activity: 1.25 hours (74 minutes)

Target Audience

This webcast is designed to meet the educational needs of rheumatologists, internal medicine physicians and other health care professionals who diagnose, treat, and manage patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and osteoarthritis.

Statement of Need / Program Overview

This webcast is intended to improve care of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and osteoarthritis by accelerating adoption of new recommendations and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 4 continuing education activities.

Click the links below to review the activity launch pages containing full disclosure information.

Module 1

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the data supporting the classification of RA by the ACR/EULAR and ACR updated treatment recommendations
  • Identify current disease-modifying anti-rheumatic drugs (DMARDs) and newer combination and biological therapies to delay disease progression and improve outcomes in patients with RA

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 1

Module 2

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize algorithm for evaluation and implementation of treatment strategies to identify psoriatic arthritis patients who may benefit from early disease-suppressing therapy
  • Identify newer biological therapies to delay disease progression and improve outcomes in patients with psoriatic arthritis

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 2

Module 3

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the key components that contribute to the pathogenesis of knee osteoarthritis and discuss current clinical data and outcomes associated with the use of chondroitin sulfate, glucosamine and hyaluronic acid
  • Identify evolving concepts of spondyloarthritis and update on treatment

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 3

Module 4

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the role of biosimilars in the treatment of early stage rheumatoid arthritis
  • Identify strategies to alleviate chronic widespread pain due to central sensitization in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 4